This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
EPIC-PEDS is a phase 3, non-randomized, single-group study evaluating nirmatrelvir and ritonavir in patients under 18 years of age with COVID-19 who are not hospitalized but are at risk for severe disease. The registry lists 160 participants and 5 arms. The primary endpoints focus on pharmacokinetic exposure in Cohorts 1-2, treatment-emergent and serious adverse events leading to discontinuation, adverse events leading to discontinuation, and changes from baseline in vital signs.
| Feature | EPIC-PEDS |
|---|---|
| Study | EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease |
| Phase | Phase 3 |
| Condition | COVID-19 |
| Allocation | Non-randomized |
| Design model | Single group |
| Masking | None |
| Primary purpose | Treatment |
| Enrollment | 160 |
| Number of arms | 5 |
| Interventions | Nirmatrelvir; ritonavir |
| Status | Recruiting |
| Lead sponsor | Pfizer |
| Sponsor type | Industry |
| ClinicalTrials.gov | NCT05261139 |
2. Clinical Question
The registry describes a phase 3 study of nirmatrelvir and ritonavir in patients under 18 years of age with COVID-19 who are not hospitalized but are at risk for severe disease. The primary statistical questions are centered on pharmacokinetic exposure and safety rather than a randomized comparison between treatments.
Population
Patients under 18 years of age with COVID-19 who are not hospitalized but are at risk for severe disease.
Intervention
Nirmatrelvir and ritonavir.
Comparator
The registry describes a non-randomized, single-group design with no masking. No separate randomized comparator is reported.
Primary questions
What are the observed plasma concentrations and exposure measures of nirmatrelvir and ritonavir in Cohorts 1-2, and what treatment-emergent safety and vital-sign changes are observed through Day 34?
3. Trial Design
The design determines what statistical comparisons are possible. EPIC-PEDS is registered as non-randomized and single-group, with no masking. That means the central statistical task is characterization of pharmacokinetics and safety rather than estimation of a randomized treatment effect.
4. Trial Timeline
Study start
The registered study start date is March 7, 2022.
Primary completion
The registered primary completion date is July 30, 2026.
Recruiting
The ClinicalTrials.gov record identifies the study status as recruiting.
5. Registered Primary Endpoints
The registry specifies six primary endpoints. They fall into three statistical families: pharmacokinetic exposure measures, safety-event incidence measures, and changes in vital signs.
| Primary endpoint | Time frame | Statistical type |
|---|---|---|
| Cohort 1-2: Maximum Observed Plasma Concentration (Cmax) of nirmatrelvir and ritonavir | Day 1: 1 hour-post dose; Day 4: pre-dose; Day 5: pre-dose, and 1, and 2 hours post dose | Pharmacokinetic exposure |
| Cohort 1-2: Area Under the Curve to the End of the Dosing Period (AUC0-tau) of nirmatrelvir and ritonavir | Day 1: 1 hour-post dose; Day 4: pre-dose; Day 5: pre-dose, and 1, and 2 hours post dose | Pharmacokinetic exposure |
| Incidence of Treatment Emergent Adverse Events (TEAEs) leading to discontinuations. | From Baseline up through Day 34 | Safety incidence |
| Incidence of Serious Adverse Events (SAEs) leading to discontinuations. | From Baseline up through Day 34 | Safety incidence |
| Incidence of Adverse Events (AEs) leading to discontinuations. | From Baseline up through Day 34 | Safety incidence |
| Number of participants with change from Baseline in Vital Signs | From Baseline up through Day 34 | Longitudinal safety assessment |
Two different kinds of information
The first two primary endpoints are pharmacokinetic measurements. They quantify drug exposure at specified sampling times. The remaining four are safety-oriented endpoints. This distinction matters because the appropriate statistical summaries for plasma concentration and exposure are different from those used for adverse-event incidence or vital signs.
6. Planned Analysis
The planned statistical interpretation is consequently centered on how these endpoint types are ordinarily summarized and evaluated.
Pharmacokinetic endpoints: Cmax and AUC0-tau
Cmax is the maximum observed plasma concentration over the specified sampling period. AUC0-tau represents exposure over the dosing interval. Both are continuous pharmacokinetic variables, and the registry specifies their assessment in Cohorts 1-2 using measurements collected on Day 1, Day 4, and Day 5.
Pharmacokinetic analyses commonly summarize concentration-derived parameters using arithmetic or geometric descriptive statistics, depending on the distribution and analysis plan. AUC and Cmax are often positively skewed, so logarithmic transformation may be useful when formal comparisons or confidence intervals are required. For a log-transformed parameter, a difference on the log scale corresponds to a ratio on the original scale.
The transformation is useful because pharmacokinetic exposure measures frequently vary multiplicatively rather than additively. The exact estimator, confidence interval procedure, and population used for EPIC-PEDS are not reported in the registry record.
Safety endpoints: adverse-event incidence
The three adverse-event primary endpoints are incidence measures through Day 34: TEAEs leading to discontinuations, SAEs leading to discontinuations, and AEs leading to discontinuations. For a single-group study, the fundamental summaries are counts and percentages of participants experiencing the specified events.
For EPIC-PEDS, the registry defines the observation period as from baseline through Day 34 for these endpoints. The appropriate denominator and handling of participants with incomplete follow-up would ordinarily be specified in the statistical analysis plan.
Vital signs
The sixth primary endpoint is the number of participants with change from baseline in vital signs from baseline through Day 34. A longitudinal safety analysis would ordinarily examine both the direction and magnitude of change, as well as clinically notable values or changes where prespecified criteria exist.
7. Statistical Methodology
Descriptive analysis is central to a single-group study
Because the registered allocation is non-randomized and the design model is single group, descriptive statistics are fundamental. There is no randomized treatment contrast from which a conventional treatment-effect hazard ratio, risk ratio, or mean difference between randomized groups can be estimated.
For continuous PK measurements, useful summaries can include measures of central tendency, variability, and distribution. For categorical safety endpoints, event counts and percentages are natural summaries. For vital signs measured repeatedly, change from baseline can be summarized over the registered follow-up period, with the exact repeated-measures method depending on the prespecified statistical analysis plan.
Pharmacokinetic concentration-time data
Cmax and AUC0-tau are derived from plasma concentration observations. Cmax is an observed maximum rather than a model coefficient. AUC0-tau summarizes the area under the concentration-time curve through the end of the dosing period.
The integral represents cumulative drug exposure over the dosing interval. In practice, AUC is generally estimated from observed concentration-time measurements using a prespecified pharmacokinetic method.
Geometric means and log transformation
When PK parameters have a skewed distribution, logarithmic transformation can make the distribution more suitable for statistical modeling. Exponentiating a mean difference on the logarithmic scale produces a ratio on the original scale.
A geometric-mean ratio describes relative exposure. It is not a percentage of participants who experienced a particular concentration, and it does not by itself establish a clinical treatment effect. Its interpretation depends on the population, sampling schedule, model, and confidence interval used.
Adverse-event incidence
Adverse-event incidence is categorical rather than continuous. A participant either does or does not meet the event definition during the specified observation period, although an individual participant can experience more than one adverse event. Analyses therefore distinguish the number of participants with at least one event from the total number of event episodes.
Vital-sign changes from baseline
Change from baseline is calculated by comparing a participant's post-baseline measurement with the corresponding baseline value. Repeated measurements create correlated observations within the same participant. A longitudinal model, repeated-measures approach, or descriptive change-from-baseline summary can therefore be considered depending on the prespecified analysis plan and the purpose of the assessment.
8. Statistical Methods Explained
Why is this not a conventional randomized treatment comparison?
The registry identifies EPIC-PEDS as non-randomized and single group. Randomization is the mechanism that balances measured and unmeasured prognostic factors in expectation between treatment groups. Without randomization, an analysis can characterize what was observed after treatment, but a comparison with an unexposed or differently treated population would not have the same randomized causal interpretation.
What does Cmax measure?
Cmax is the maximum observed plasma concentration at the specified sampling times. It is a measure of peak observed exposure. Because it is derived from concentration measurements, its precision depends on the sampling schedule, assay measurements, and biological variability.
What does AUC0-tau measure?
AUC0-tau summarizes total drug exposure from time zero through the end of the dosing period. Unlike Cmax, which focuses on the highest observed concentration, AUC integrates the concentration-time profile over the specified interval.
Why might PK parameters be log-transformed?
Exposure measures such as AUC and Cmax can have right-skewed distributions. Log transformation can make multiplicative differences easier to model and can produce a more symmetric distribution. When transformed estimates are returned to the original scale, the resulting comparison is naturally interpreted as a geometric-mean ratio.
How should an adverse-event incidence measure be interpreted?
An incidence percentage describes the proportion of participants who meet the specified event definition during the defined observation period. It does not measure event severity, duration, recurrence, or causality by itself. Those characteristics require additional clinical and statistical summaries.
Why is Day 34 important for the safety endpoints?
The registry explicitly defines the time frame for TEAEs leading to discontinuations, SAEs leading to discontinuations, AEs leading to discontinuations, and changes from baseline in vital signs as from baseline through Day 34. A safety estimate therefore has to be interpreted within that specified observation window.
9. Primary Endpoint Analysis Framework
| Endpoint family | Primary endpoint | Typical statistical treatment |
|---|---|---|
| Pharmacokinetics | Cmax of nirmatrelvir and ritonavir in Cohorts 1-2 | Descriptive PK summaries; potentially log-scale analysis and geometric means where prespecified |
| Pharmacokinetics | AUC0-tau of nirmatrelvir and ritonavir in Cohorts 1-2 | Descriptive PK summaries; potentially log-scale analysis and geometric means where prespecified |
| Safety | TEAEs leading to discontinuations | Participant counts and incidence proportions through Day 34 |
| Safety | SAEs leading to discontinuations | Participant counts and incidence proportions through Day 34 |
| Safety | AEs leading to discontinuations | Participant counts and incidence proportions through Day 34 |
| Vital signs | Participants with change from baseline in vital signs | Change-from-baseline summaries and potentially longitudinal or categorical assessments |
The table describes statistical approaches commonly used for these endpoint types. It should not be read as a statement that every listed method was formally specified for EPIC-PEDS; the registry record identifies the endpoints and time frames but does not post a formal statistical analysis for them.
10. PK Sampling Structure
The two pharmacokinetic primary endpoints in Cohorts 1-2 use a defined set of sampling times. The schedule includes observations around dosing on Day 1 and Day 5, with a pre-dose measurement on Day 4 as well.
| Day | Sampling times listed in the registry | Role |
|---|---|---|
| Day 1 | 1 hour-post dose | Pharmacokinetic concentration measurement |
| Day 4 | pre-dose | Pharmacokinetic concentration measurement |
| Day 5 | pre-dose; 1 hour post dose; 2 hours post dose | Pharmacokinetic concentration measurements |
The statistical consequence of a prespecified sampling schedule is important: Cmax and AUC0-tau are derived from the observed concentration-time profile. The sampling design therefore determines which features of that profile can be directly observed and estimated.
Cmax
Focuses on the maximum observed concentration among the available measurements.
AUC0-tau
Focuses on cumulative exposure over the dosing interval rather than the single highest concentration.
Pre-dose observations
Provide concentration measurements immediately before the relevant dose at the specified study day.
Post-dose observations
Capture concentrations at the specified times after dosing and contribute to characterization of exposure.
11. Safety Endpoint Framework
The three adverse-event primary endpoints are narrowly defined around events leading to discontinuation. That definition is statistically important because an incidence estimate for discontinuation-causing events is not equivalent to the incidence of all adverse events.
| Endpoint | Observation period | Core quantity |
|---|---|---|
| TEAEs leading to discontinuations | From Baseline up through Day 34 | Number and proportion of participants with qualifying TEAEs leading to discontinuation |
| SAEs leading to discontinuations | From Baseline up through Day 34 | Number and proportion of participants with qualifying SAEs leading to discontinuation |
| AEs leading to discontinuations | From Baseline up through Day 34 | Number and proportion of participants with qualifying AEs leading to discontinuation |
| Change from Baseline in Vital Signs | From Baseline up through Day 34 | Number of participants with changes from baseline in vital signs |
These endpoints should be interpreted at the participant level unless a formal analysis plan defines a different estimand. In particular, the incidence of participants with an event is not interchangeable with the total number of adverse-event occurrences.
12. Missing Data and Follow-Up
The registered safety endpoints use a fixed observation window from baseline through Day 34. In a longitudinal clinical trial, participants can have incomplete observations, discontinue treatment, or miss individual assessments. The statistical handling of those situations can materially affect a calculated incidence or change-from-baseline summary.
The registry record does not report a posted statistical analysis specifying an imputation method, censoring rule, or missing-data model for these endpoints. For descriptive safety analyses, investigators commonly distinguish participants who are evaluable for an assessment from participants who have incomplete observations. For repeated vital-sign measurements, the treatment of intermittent missing observations would ordinarily be determined by the prespecified analysis plan.
13. Analysis Population Considerations
The registry lists enrollment of 160 participants, but the information available here does not provide separate analysis-population counts for the PK and safety endpoints. Those populations can differ in practice because pharmacokinetic analyses may require evaluable concentration measurements, while safety analyses are generally tied to treatment exposure and safety follow-up.
14. What Can and Cannot Be Inferred From This Design
What the design supports
Characterization of observed pharmacokinetic exposure, safety-event incidence, and changes in vital signs over the registered follow-up period.
What the design does not provide directly
A randomized estimate of the difference in outcomes between nirmatrelvir/ritonavir and a separate control treatment.
This distinction is fundamental. A single-group study can provide detailed information about exposure and observed safety. It cannot, by randomization alone, separate treatment-associated differences from differences that would have occurred without treatment.
The same principle applies to any numerical estimate. A confidence interval around a single-group mean, geometric mean, or incidence proportion quantifies sampling uncertainty for that quantity. It does not transform the study into a randomized comparison.
15. Statistical Interpretation of the Primary Endpoint Families
Cmax and AUC0-tau are exposure parameters. Higher or lower values describe differences in observed pharmacokinetic exposure, but an exposure parameter by itself is not a clinical outcome. Its interpretation depends on the drug, dosing regimen, population, sampling schedule, and prespecified PK analysis.
An adverse-event incidence proportion answers the question: what proportion of participants experienced the specified event during the defined period? It does not by itself establish causality, severity, duration, or comparative risk.
A change-from-baseline measurement describes how a participant's vital-sign value differs from baseline. It does not automatically indicate a clinically important abnormality; clinical interpretation requires the measurement, magnitude of change, timing, and any prespecified clinical thresholds.
16. Non-Randomization and Causal Interpretation
Randomization is not simply a technical feature of trial administration. It is the statistical mechanism that makes treatment groups comparable in expectation with respect to both measured and unmeasured characteristics. EPIC-PEDS is registered as non-randomized, so its principal statistical role is different.
For example, if an observed safety event occurs after treatment, temporal sequence alone does not establish that the treatment caused the event. Safety assessment incorporates clinical attribution and the broader pattern of events. Likewise, an observed change in a vital sign after treatment can be described without assuming that every change was caused by treatment.
17. Multiplicity, Interim Analysis, and Bayesian Methods
The registry information does not report a multiplicity strategy, an interim-analysis framework, or Bayesian methods for the primary endpoints. Those design elements should therefore not be assumed from the presence of multiple endpoints.
There are six registered primary endpoints, including two pharmacokinetic endpoints and four safety-oriented endpoints. Having multiple endpoints does not automatically imply that every endpoint is tested with a conventional hypothesis test or that a familywise type I error adjustment is required. The appropriate interpretation depends on whether the endpoints are descriptive, confirmatory, or part of a formal decision rule.
| Design topic | What the registry reports | Statistical implication |
|---|---|---|
| Multiplicity | No strategy reported | No specific multiplicity procedure can be characterized from the registry information. |
| Interim analysis | No interim-analysis method reported | No alpha-spending or group-sequential framework can be characterized. |
| Bayesian methods | No Bayesian method reported | No prior distribution or posterior analysis can be described. |
| Randomization | Non-randomized | No randomized treatment-effect comparison is defined by the design. |
| Masking | None | The study is registered as unmasked. |
18. Why Cmax and AUC Should Not Be Treated as the Same Endpoint
Cmax and AUC summarize different dimensions of the concentration-time profile. Cmax emphasizes the peak observed concentration, whereas AUC0-tau summarizes cumulative exposure over the dosing interval.
| Feature | Cmax | AUC0-tau |
|---|---|---|
| Primary concept | Maximum observed plasma concentration | Area under the curve to the end of the dosing period |
| What it emphasizes | Peak exposure | Total exposure over the interval |
| Dependence on sampling | Strongly dependent on whether the observed maximum is captured | Depends on the concentration-time measurements used to estimate the area |
| Typical scale | Concentration | Concentration × time |
A study can therefore characterize peak and cumulative exposure separately. A change in Cmax does not necessarily imply a proportionate change in AUC0-tau, because the two parameters summarize different aspects of the pharmacokinetic profile.
19. Why This Trial Matters Statistically
EPIC-PEDS is a useful teaching case because it illustrates a type of clinical-trial analysis that is fundamentally different from a randomized superiority trial. The primary statistical questions involve pharmacokinetic characterization and safety surveillance within a non-randomized, single-group framework.
| Concept | How it appears in EPIC-PEDS |
|---|---|
| Single-group design | The registry identifies the design model as single group. |
| Non-randomized allocation | The allocation field is non-randomized. |
| Pharmacokinetics | Cmax and AUC0-tau are primary endpoints for Cohorts 1-2. |
| Concentration-time sampling | PK sampling is specified on Day 1, Day 4, and Day 5 at defined times. |
| Safety incidence | TEAEs, SAEs, and AEs leading to discontinuations are primary endpoints. |
| Fixed observation window | Safety and vital-sign endpoints are assessed from baseline through Day 34. |
| Longitudinal safety | Change from baseline in vital signs is a primary endpoint. |
| Analysis-population distinction | The PK endpoints are specifically defined for Cohorts 1-2, while overall enrollment is 160. |
20. Limitations
- No randomized comparator: the registered design is non-randomized and single group, limiting causal interpretation of observed outcomes.
- No formal statistical analyses posted: the ClinicalTrials.gov record does not currently provide numerical statistical analyses for the registered primary endpoints.
- Limited arm-level detail: the registry lists 5 arms but does not provide the arm-specific sample sizes or additional arm-level treatment descriptions needed for a detailed arm-by-arm statistical comparison.
- PK population specificity: the Cmax and AUC0-tau endpoints are explicitly limited to Cohorts 1-2, while the registered enrollment is 160 participants overall.
- Missing-data rules: the registry information does not specify an imputation method or detailed rules for incomplete PK, safety, or vital-sign observations.
- No posted multiplicity strategy: the available registry information does not identify a formal adjustment or endpoint hierarchy for the six primary endpoints.
- No posted interim framework: the available registry information does not specify interim analyses or alpha spending.
- Safety incidence is not causality: an event occurring during the observation window does not by itself establish that treatment caused the event.
- Vital-sign changes require context: a change from baseline does not automatically constitute a clinically meaningful abnormality.
- Registry status: the record identifies the study as recruiting, so the registry information should be interpreted as a study record rather than a posted final statistical results report.
21. Results Status and Interpretation
The ClinicalTrials.gov record identifies EPIC-PEDS as recruiting and does not post formal statistical analyses for the six registered primary endpoints. Consequently, the statistically informative material currently available from the record is the study design, endpoint definitions, sampling schedule, observation windows, and registered enrollment rather than treatment-effect estimates or numerical PK and safety outcomes.
Current statistical evidence
The registry contains no posted statistical analyses for the registered primary endpoints.
The appropriate interpretation is therefore based on the endpoint structure and study design rather than on numerical outcome estimates.
This distinction is particularly important for EPIC-PEDS. A phase 3 designation does not itself mean that a randomized treatment effect is available. The registered allocation and design model remain the key determinants of what statistical comparisons the study can support.
22. Sources
- ClinicalTrials.gov: EPIC-PEDS (NCT05261139).
Continue through the Clinical Biostats knowledge graph
Clinical trial analysis connects study design, endpoint definitions, pharmacokinetic methods, safety analysis, and the statistical principles used to interpret observed data.
23. Record Summary
EPIC-PEDS is registered as a phase 3, non-randomized, single-group study of nirmatrelvir and ritonavir in patients under 18 years of age with COVID-19 who are not hospitalized but are at risk for severe disease. The registry lists 160 participants and 5 arms. Its six primary endpoints combine pharmacokinetic exposure measures in Cohorts 1-2 with safety and vital-sign assessments through Day 34.
Statistically, the study illustrates why the design determines the appropriate analysis. Cmax and AUC0-tau are continuous pharmacokinetic exposure measures that are commonly summarized using concentration-time and, where appropriate, log-scale methods. Adverse-event endpoints are participant-level incidence measures defined over a fixed observation period. Vital-sign changes require longitudinal consideration because measurements can be repeated within participants.
Because the registry does not post formal statistical analyses or numerical endpoint results, the current record supports an analysis of the planned statistical framework rather than a numerical reconstruction of treatment effects. The central lesson is that descriptive PK and safety characterization in a single-group study should not be interpreted as equivalent to evidence from a randomized controlled comparison.